MIRADENZ Trademark

Trademark Overview

On Tuesday, April 5, 2016, a trademark application was filed for MIRADENZ with the United States Patent and Trademark Office. The USPTO has given the MIRADENZ trademark a serial number of 86965134. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Monday, March 23, 2020. This trademark is owned by Pfizer Inc.. The MIRADENZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, anti-fungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
miradenz

General Information

Serial Number86965134
Word MarkMIRADENZ
Filing DateTuesday, April 5, 2016
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateMonday, March 23, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 19, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, anti-fungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use
Translation of Words in MarkThe word(s) "MIRADENZ" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateMonday, March 23, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, March 23, 2020ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Monday, March 23, 2020ABANDONMENT - AFTER PUBLICATION
Friday, March 20, 2020TEAS EXPRESS ABANDONMENT RECEIVED
Wednesday, March 18, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 18, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 18, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, March 18, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, March 18, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, March 18, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, December 16, 2019EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, November 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 19, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 30, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 15, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 24, 2019LIE CHECKED SUSP - TO ATTY FOR ACTION
Tuesday, September 24, 2019ASSIGNED TO LIE
Wednesday, March 13, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, August 31, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, August 31, 2018ASSIGNED TO LIE
Wednesday, February 21, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, August 16, 2017REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, February 10, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, February 10, 2017LETTER OF SUSPENSION E-MAILED
Friday, February 10, 2017SUSPENSION LETTER WRITTEN
Wednesday, February 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 8, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 31, 2017ASSIGNED TO LIE
Wednesday, January 11, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 25, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 25, 2016NON-FINAL ACTION E-MAILED
Monday, July 25, 2016NON-FINAL ACTION WRITTEN
Tuesday, July 19, 2016ASSIGNED TO EXAMINER
Monday, April 11, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, April 8, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

miradenz preparations pharmaceutical dysfunction treatment cancer diabetes sexual pain disorders diseases